Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M.

Lancet Oncol. 2019 Jan 15. pii: S1470-2045(18)30784-8. doi: 10.1016/S1470-2045(18)30784-8. [Epub ahead of print]

PMID:
30658935
2.

Functional pathways associated with human carotid atheroma: a proteomics analysis.

Nehme A, Kobeissy F, Zhao J, Zhu R, Feugier P, Mechref Y, Zibara K.

Hypertens Res. 2019 Jan 7. doi: 10.1038/s41440-018-0192-4. [Epub ahead of print]

PMID:
30617313
3.

Treatment of Complex Aortic Aneurysms Using Combination of Renal and Visceral Bypass and Fenestrated/Branched Stent Grafts.

Duprey A, Ben Ahmed S, Della Schiava N, Feugier P, Rosset E, Favre JP, Chavent B, Albertini JN.

Ann Vasc Surg. 2018 Nov 27. pii: S0890-5096(18)30904-X. doi: 10.1016/j.avsg.2018.09.025. [Epub ahead of print]

PMID:
30500648
4.

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.

Houot R, Cartron G, Bijou F, de Guibert S, Salles GA, Fruchart C, Bouabdallah K, Maerevoet M, Feugier P, Le Gouill S, Tilly H, Casasnovas RO, Moluçon-Chabrot C, Van Den Neste E, Zachee P, Andre M, Bonnet C, Haioun C, Van Hoof A, Van Eygen K, Molina L, Nicolas-Virelizier E, Ruminy P, Morschhauser F.

Leukemia. 2018 Oct 5. doi: 10.1038/s41375-018-0282-y. [Epub ahead of print] No abstract available.

PMID:
30291335
5.

Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group.

Roos-Weil D, Nguyen-Khac F, Chevret S, Touzeau C, Roux C, Lejeune J, Cosson A, Mathis S, Feugier P, Leprêtre S, Béné MC, Baron M, Raynaud S, Struski S, Eclache V, Sutton L, Lesty C, Merle-Béral H, Cymbalista F, Ysebaert L, Davi F, Leblond V; FILO working group.

Genes Chromosomes Cancer. 2018 Nov;57(11):533-540. doi: 10.1002/gcc.22650. Epub 2018 Sep 11.

PMID:
30203893
6.

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators.

N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104.

PMID:
30184451
7.

Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.

Tilly H, Morschhauser F, Casasnovas O, Molina TJ, Feugier P, Gouill SL, Haioun C, Tournilhac O, Bouabdallah R, Gabarre J, Lamy T, Cabeçadas J, Becker S, Jardin F, Mounier N, Salles G; Lymphoma Study Association.

Lancet Haematol. 2018 Sep;5(9):e403-e410. doi: 10.1016/S2352-3026(18)30131-5.

PMID:
30172345
8.

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.

Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Pignon JM, Corm S, Banos A, Mounier C, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouadallah K, Amorin S, Garidi R, Voillat L, Joly B, Celigny PS, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Le Gouill S, Callanan MB; Lymphoma Study Association.

Haematologica. 2019 Jan;104(1):138-146. doi: 10.3324/haematol.2018.191429. Epub 2018 Aug 31.

9.

Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.

Gyan E, Sonet A, Brice P, Anglaret B, Laribi K, Fruchart C, Tilly H, Araujo C, Soubeyran P, Gonzalez H, Morineau N, Nicolas-Virelizier E, Ghesquières H, Salles B, Bouabdallah R, Orfeuvre H, Fahri J, Couturier O, Xerri L, Feugier P; Lymphoma Study Association (LYSA).

Br J Haematol. 2018 Oct;183(1):76-86. doi: 10.1111/bjh.15513. Epub 2018 Aug 16.

PMID:
30117149
10.

Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia?

Filliatre-Clement L, Broseus J, Muller M, Hosseini K, Rotonda C, Schirmer L, Roth-Guepin G, Bonmati C, Feugier P, Béné MC, Perrot A.

Hematol Oncol. 2018 Aug 13. doi: 10.1002/hon.2543. [Epub ahead of print]

PMID:
30105853
11.

Idelalisib in a patient with refractory Waldenström's macroglobulinemia complicated by anuric renal failure: a case report.

D'Aveni-Piney M, Divoux M, Busby-Venner H, Muller M, Broséus J, Feugier P.

J Med Case Rep. 2018 Jun 12;12(1):164. doi: 10.1186/s13256-018-1694-z.

12.

Effects on Mortality and Cardiovascular Events of Adherence to Guideline-Recommended Therapy 4 Years after Lower Extremity Arterial Revascularization.

Thiney M, Della Schiava N, Ecochard R, Feugier P, Lermusiaux P, Millon A, Long A.

Ann Vasc Surg. 2018 Oct;52:138-146. doi: 10.1016/j.avsg.2018.03.021. Epub 2018 May 17.

PMID:
29777848
13.

Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.

Feugier P, Aurran T, Mahé B, Letestu R, Nguyen-Khac F, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Cymbalista F, Ross-Weil D, Leprêtre S.

Haematologica. 2018 Jul;103(7):e304-e306. doi: 10.3324/haematol.2017.183350. Epub 2018 Mar 15. No abstract available.

14.

Ulnar-basilic vein transposition on radial artery for home parenteral nutrition.

Della Schiava N, Arsicot M, Boudjelit T, Chambrier C, Moia A, Herail J, Roquet G, Favier de Lachomette M, Feugier P, Millon A, Lermusiaux P.

J Vasc Access. 2018 Jul;19(4):414-415. doi: 10.1177/1129729817747539. Epub 2018 Mar 14. No abstract available.

PMID:
29536788
15.

Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.

Cartron G, Letestu R, Dartigeas C, Tout M, Mahé B, Gagez AL, Ferrant E, Guiu B, Villemagne B, Letuan P, Aurran T, Orsini-Piocelle F, Banos A, Feugier P, Leblond V, de Guibert S, Tournilhac O, Dupuis J, Delmer A, Rouillé V, Ternant D, Leprêtre S.

Haematologica. 2018 Aug;103(8):e356-e359. doi: 10.3324/haematol.2017.182352. Epub 2018 Mar 8. No abstract available.

16.

Management of relapsed or refractory follicular lymphoma patients in daily practice - a French non-interventional study.

Feugier P, Brice P, Maynadié M, Franchi-Rezgui P, Hacini M, Laurent G, Suc E, Fitoussi O, Solal-Celigny P, Damaj G, Haioun C, Leconte P, Lazreg F, Boissard F, Pau D, Salles G.

Leuk Lymphoma. 2018 Oct;59(10):2485-2488. doi: 10.1080/10428194.2018.1434878. Epub 2018 Feb 28. No abstract available.

PMID:
29486625
17.

A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.

Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carrère M, Xerri L, Ansell SM, Baseggio L, Reyes C, Tarte K, Boyault S, Haioun C, Link BK, Feugier P, Lopez-Guillermo A, Tilly H, Brice P, Hayette S, Jardin F, Offner F, Sujobert P, Gentien D, Viari A, Campo E, Cerhan JR, Salles G.

Lancet Oncol. 2018 Apr;19(4):549-561. doi: 10.1016/S1470-2045(18)30102-5. Epub 2018 Feb 20. Erratum in: Lancet Oncol. 2018 Jun;19(6):e283.

18.

Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.

Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Leprêtre S, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahé B, Laribi K, Michallet AS, Delmer A, Feugier P, Lévy V, Delépine R, Colombat P, Leblond V; CLL 2007 SA investigators; French Innovative Leukemia Organization (FILO).

Lancet Haematol. 2018 Feb;5(2):e82-e94. doi: 10.1016/S2352-3026(17)30235-1. Epub 2017 Dec 20.

PMID:
29275118
19.

Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group.

Guillermin Y, Herbaux C, Subtil F, Aurran-Schleinitz T, Cymbalista F, Letestu R, Leprêtre S, Vaudaux S, Laribi K, Leblond V, Defoi Y, Benchikh R, Salles G, Godmer P, Jardel H, Vallais F, Feugier P, Orsini F, Pegourié B, Lévy V, Michallet AS.

Am J Hematol. 2018 Jan;93(1):E24-E27. doi: 10.1002/ajh.24951. Epub 2017 Nov 17. No abstract available.

20.

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O; LYSA Group.

N Engl J Med. 2017 Sep 28;377(13):1250-1260. doi: 10.1056/NEJMoa1701769.

21.

FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.

Casasnovas RO, Ysebaert L, Thieblemont C, Bachy E, Feugier P, Delmer A, Tricot S, Gabarre J, Andre M, Fruchart C, Mounier N, Delarue R, Meignan M, Berriolo-Riedinger A, Bardet S, Emile JF, Jais JP, Haioun C, Tilly H, Morschhauser F.

Blood. 2017 Sep 14;130(11):1315-1326. doi: 10.1182/blood-2017-02-766691. Epub 2017 Jul 12.

22.

A Meta-Analysis of Outcomes After In Situ Reconstructions for Aortic Graft Infection.

Batt M, Feugier P, Camou F, Coffy A, Senneville E, Caillon J, Calvet B, Chidiac C, Laurent F, Revest M, Daures JP; Research Group for Vascular Graft Infection.

Angiology. 2018 May;69(5):370-379. doi: 10.1177/0003319717710114. Epub 2017 Jun 5.

PMID:
28578619
23.

Endovascular Repair of a Short Neck Abdominal Aortic Aneurysm with a Physician-Modified Vascutek Anaconda Stent Graft.

Duprey A, Ben Ahmed S, Millon A, Feugier P, Favre JP, Albertini JN.

Ann Vasc Surg. 2017 Aug;43:317.e5-317.e11. doi: 10.1016/j.avsg.2017.04.043. Epub 2017 May 8.

PMID:
28495541
24.

Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.

Ysebaert L, Aurran-Schleinitz T, Dartigeas C, Dilhuydy MS, Feugier P, Michallet AS, Tournilhac O, Dupuis J, Sinet P, Albrecht C, Cymbalista F.

Am J Hematol. 2017 Aug;92(8):E166-E168. doi: 10.1002/ajh.24773. Epub 2017 May 30. No abstract available.

25.

Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1.

Cosson A, Chapiro E, Bougacha N, Lambert J, Herbi L, Cung HA, Algrin C, Keren B, Damm F, Gabillaud C, Brunelle-Navas MN, Davi F, Merle-Béral H, Le Garff-Tavernier M, Roos-Weil D, Choquet S, Uzunov M, Morel V, Leblond V, Maloum K, Lepretre S, Feugier P, Lesty C, Lejeune J, Sutton L, Landesman Y, Susin SA, Nguyen-Khac F.

Leukemia. 2017 Jul;31(7):1625-1629. doi: 10.1038/leu.2017.100. Epub 2017 Mar 27. No abstract available.

PMID:
28344316
26.

BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.

Petrella T, Copie-Bergman C, Brière J, Delarue R, Jardin F, Ruminy P, Thieblemont C, Figeac M, Canioni D, Feugier P, Fabiani B, Leroy K, Parrens M, André M, Haioun C, Salles GA, Gaulard P, Tilly H, Jais JP, Molina TJ.

Ann Oncol. 2017 May 1;28(5):1042-1049. doi: 10.1093/annonc/mdx022.

PMID:
28327893
27.

Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.

Michallet AS, Campidelli A, Lequeu H, Dilhuydy MS, Tournilhac O, Fornecker LM, Dupuis J, Cymbalista F, De Guibert S, Delmer A, Vilque JP, Ghez D, Leblond V, Subtil F, Feugier P, Ysebaert L.

Am J Hematol. 2017 Jun;92(6):E105-E107. doi: 10.1002/ajh.24715. Epub 2017 Apr 29. No abstract available.

28.

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.

Tout M, Casasnovas O, Meignan M, Lamy T, Morschhauser F, Salles G, Gyan E, Haioun C, Mercier M, Feugier P, Boussetta S, Paintaud G, Ternant D, Cartron G.

Blood. 2017 May 11;129(19):2616-2623. doi: 10.1182/blood-2016-10-744292. Epub 2017 Mar 1.

29.

BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab.

Huet S, Szafer-Glusman E, Tesson B, Xerri L, Fairbrother WJ, Mukhyala K, Bolen C, Punnoose E, Tonon L, Chassagne-Clément C, Feugier P, Viari A, Jardin F, Salles G, Sujobert P.

Am J Hematol. 2017 Jun;92(6):515-519. doi: 10.1002/ajh.24701. Epub 2017 Mar 24.

30.

Popliteal Artery Entrapment Syndrome in Children: Experience With Four Cases of Acute Ischaemia and Review of the Literature.

Settembre N, Bouziane Z, Bartoli MA, Nabokov V, Venermo M, Feugier P, Malikov S.

Eur J Vasc Endovasc Surg. 2017 Apr;53(4):576-582. doi: 10.1016/j.ejvs.2016.12.032. Epub 2017 Feb 17. Review.

31.

[Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment].

Anthony S, Hebel P, Garrel A, Oliveri V, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Delarue R, Ysebaert L, Sebban C, Broussais F, Damaj G, Nerich V, Jais JP, Salles G, Henry-Amar M, Mounier N.

Bull Cancer. 2017 Mar;104(3):221-231. doi: 10.1016/j.bulcan.2017.01.007. Epub 2017 Feb 15. French.

PMID:
28214006
32.

[Inflammation in the perivascular adipose tissue and atherosclerosis].

Hamlat-Khennaf N, Neggazi S, Ayari H, Feugier P, Bricca G, Aouichat-Bouguerra S, Beylot M.

C R Biol. 2017 Mar;340(3):156-163. doi: 10.1016/j.crvi.2017.01.001. Epub 2017 Feb 7. French.

PMID:
28188070
33.

How Admission to a Vascular Surgery Department Improves Medical Treatment in Patients with Lower Extremity Peripheral Arterial Disease.

Thiney M, Della Schiava N, Feugier P, Lermusiaux P, Ninet J, Millon A, Long A.

Ann Vasc Surg. 2017 Apr;40:85-93. doi: 10.1016/j.avsg.2016.08.030. Epub 2016 Nov 28.

PMID:
27908822
34.

First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.

Meunier G, Ysebaert L, Nguyen-Thi PL, Lepretre S, Quinquenel A, Dupuis J, Lemal R, Aurran T, Tomowiak C, Cymbalista F, Dilhuydy MS, Brion A, Morel P, Cazin B, Leblond V, Cartron G, Ré D, Béné MC, Michallet AS, Feugier P.

Hematol Oncol. 2017 Dec;35(4):671-678. doi: 10.1002/hon.2370. Epub 2016 Nov 22.

PMID:
27878835
35.

A multicenter experience with infected abdominal aortic endograft explantation.

Chaufour X, Gaudric J, Goueffic Y, Khodja RH, Feugier P, Malikov S, Beraud G, Ricco JB; AURC (French University Surgeons Association) collaborators.

J Vasc Surg. 2017 Feb;65(2):372-380. doi: 10.1016/j.jvs.2016.07.126. Epub 2016 Oct 5.

PMID:
27720319
36.

Renal Function after Fenestrated or Branched Endovascular Aortic Repair: The Early Impairment Predictive Factors.

de Lachomette MF, Della N, Maucort-Boulch D, Duprey A, Rosset E, Feugier P, Lermusiaux P, Albertini JN, Millon A.

Ann Vasc Surg. 2017 Apr;40:1-9. doi: 10.1016/j.avsg.2016.06.014. Epub 2016 Aug 27.

PMID:
27575304
37.

Locally advanced pancreatic duct adenocarcinoma: pancreatectomy with planned arterial resection based on axial arterial encasement.

Perinel J, Nappo G, El Bechwaty M, Walter T, Hervieu V, Valette PJ, Feugier P, Adham M.

Langenbecks Arch Surg. 2016 Dec;401(8):1131-1142. Epub 2016 Jul 30.

PMID:
27476146
38.

Conformability of GORE Excluder Iliac Branch Endoprosthesis and COOK Zenith Bifurcated Iliac Side Branched Iliac Stent Grafts.

Della Schiava N, Arsicot M, Boudjelit T, Feugier P, Lermusiaux P, Millon A.

Ann Vasc Surg. 2016 Oct;36:139-144. doi: 10.1016/j.avsg.2016.02.042. Epub 2016 Jul 6.

PMID:
27395814
39.

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.

Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M; European Mantle Cell Lymphoma Network.

Lancet. 2016 Aug 6;388(10044):565-75. doi: 10.1016/S0140-6736(16)00739-X. Epub 2016 Jun 14.

PMID:
27313086
40.

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.

Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, Brice P, Soubeyran P, Gomes Da Silva M, Mounier C, Offner F, Dupuis J, Caballero D, Canioni D, Paula M, Delarue R, Zachee P, Seymour J, Salles G, Tilly H.

J Clin Oncol. 2016 Aug 1;34(22):2575-82. doi: 10.1200/JCO.2015.65.7163. Epub 2016 Jun 13. Erratum in: J Clin Oncol. 2016 Sep 10;34(26):3230.

PMID:
27298402
41.

Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.

Broséus J, Chen G, Hergalant S, Ramstein G, Mounier N, Guéant JL, Feugier P, Gisselbrecht C, Thieblemont C, Houlgatte R.

Oncotarget. 2016 Dec 20;7(51):83987-84002. doi: 10.18632/oncotarget.9793.

42.

Sporadic intra-abdominal desmoid tumor: a unusual presentation.

Lasseur A, Pasquer A, Feugier P, Poncet G.

J Surg Case Rep. 2016 May 5;2016(5). pii: rjw070. doi: 10.1093/jscr/rjw070.

43.

Cryopreserved Arterial Allografts and ABO and Rhesus Compatibility.

Della Schiava N, Mathevet JL, Boudjelit T, Arsicot M, Feugier P, Lermusiaux P, Millon A.

Ann Vasc Surg. 2016 May;33:173-80. doi: 10.1016/j.avsg.2015.11.014. Epub 2016 Feb 22.

PMID:
26916349
44.

Amplatzer Plug to Occlude the Internal Iliac Artery During Endovascular Aortic Aneurysm Repair: A Large Multicenter Study.

Warein E, Feugier P, Chaufour X, Molin V, Malikov S, Bartoli MA, Coscas R, Picquet J, Peyrot H, Favre JP, Steinmetz E, Ben Ahmed S, Rosset E; AURC (Association Universitaire de Recherche en Chirurgie) – University Association for Research in Surgery.

Eur J Vasc Endovasc Surg. 2016 May;51(5):641-6. doi: 10.1016/j.ejvs.2015.12.021. Epub 2016 Feb 12.

45.

Preliminary Experience with the GORE(®) EXCLUDER(®) Iliac Branch Endoprosthesis for Common Iliac Aneurysm Endovascular Treatment.

Millon A, Della Schiava N, Arsicot M, De Lambert A, Feugier P, Magne JL, Lermusiaux P.

Ann Vasc Surg. 2016 May;33:11-7. doi: 10.1016/j.avsg.2015.12.003. Epub 2016 Jan 22.

PMID:
26808286
46.

Acute Ischemia due to Superficial Femoral Artery Thrombosis: Results of In Situ Fibrinolysis.

Arsicot M, Della Schiava N, Boudjelit T, Rouvière O, Feugier P, Lermusiaux P, Millon A.

Ann Vasc Surg. 2016 May;33:31-8. doi: 10.1016/j.avsg.2015.10.029. Epub 2016 Jan 22.

PMID:
26806234
47.

Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups.

Gagez AL, Tuaillon E, Cezar R, Dartigeas C, Mahé B, Letestu R, Maisonneuve H, Gouilleux-Gruart V, Bollore K, Ferrant E, Aurran T, Feugier P, Leprêtre S, Cartron G.

Blood Cancer J. 2016 Jan 22;6:e389. doi: 10.1038/bcj.2015.115. No abstract available.

48.

Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials.

Maraldo MV, Giusti F, Vogelius IR, Lundemann M, van der Kaaij MA, Ramadan S, Meulemans B, Henry-Amar M, Aleman BM, Raemaekers J, Meijnders P, Moser EC, Kluin-Nelemans HC, Feugier P, Casasnovas O, Fortpied C, Specht L; European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group.

Lancet Haematol. 2015 Nov;2(11):e492-502. doi: 10.1016/S2352-3026(15)00153-2. Epub 2015 Oct 22.

PMID:
26686259
49.

Randomized Study of Noninferiority Comparing Prosthetic and Autologous Vein Above-Knee Femoropopliteal Bypasses.

Midy D, Papon X, Patra P, Hassen Kodja R, Feugier P, Plissonnier D, Reix T, Chene G, Berard X; Association Universitaire de Recherche en Chirurgie Vasculaire (AURC); Association Universitaire de Recherche en Chirurgie Vasculaire AURC.

Ann Vasc Surg. 2016 Feb;31:99-104. doi: 10.1016/j.avsg.2015.07.047. Epub 2015 Nov 26.

PMID:
26631773
50.

High-resolution MRI: detection of a culprit plaque after recurrent thrombolysis.

Mechtouff L, Ritzenthaler T, Cho TH, Derex L, Feugier P, Berthezene Y, Collet-Benzaquen D, Douek PC, Nighoghossian N.

J Neurol. 2015 Dec;262(12):2773-5. doi: 10.1007/s00415-015-7915-0. Epub 2015 Nov 3. No abstract available.

PMID:
26530507

Supplemental Content

Loading ...
Support Center